MQS Management LLC Makes New $162,000 Investment in Certara, Inc. (NASDAQ:CERT)

MQS Management LLC acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 11,710 shares of the company’s stock, valued at approximately $162,000.

Several other institutional investors and hedge funds have also modified their holdings of CERT. Dimensional Fund Advisors LP boosted its holdings in shares of Certara by 9.7% in the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Certara by 9.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after purchasing an additional 248,448 shares during the period. Envestnet Asset Management Inc. boosted its stake in Certara by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 573,660 shares of the company’s stock worth $7,945,000 after purchasing an additional 43,403 shares during the period. Oppenheimer Asset Management Inc. increased its holdings in Certara by 45.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 197,724 shares of the company’s stock worth $2,738,000 after purchasing an additional 61,980 shares in the last quarter. Finally, Choreo LLC acquired a new stake in shares of Certara in the 2nd quarter valued at about $348,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Price Performance

NASDAQ:CERT opened at $10.90 on Friday. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $13.26 and a 200 day simple moving average of $15.40. Certara, Inc. has a 1-year low of $10.35 and a 1-year high of $19.87. The stock has a market capitalization of $1.75 billion, a PE ratio of -27.95, a P/E/G ratio of 5.23 and a beta of 1.49.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, research analysts expect that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CERT shares. Barclays decreased their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Robert W. Baird lowered their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. JMP Securities restated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. UBS Group lowered their price target on shares of Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, KeyCorp cut their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Certara presently has an average rating of “Hold” and an average price target of $17.79.

Insiders Place Their Bets

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.39% of the company’s stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.